California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

In the rapidly evolving landscape of pharmaceutical development, AI promises to revolutionize the entire drug discovery and development process, impacting target discovery, clinical trial design, site ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...

From The Editor Leadership For Tomorrow Feature Articles Executive Outlook: Converting Innovative Science Into Predictable Returns Manufacturing And Supply Chain: Making Space Between A Rock And A ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...